Supertech eyes Rs. 3,000 crore sales target for FY18


North India’s leading real estate developer Supertech Limited announced that company is on track to achieve its sales target of Rs. 3000 crore by March 2018. The company is selling almost 300 apartments month on a month basis across its 40 projects in 50 locations.

Supertech said it has majorly been selling in affordable segment of price band ranging between Rs. 25 to 70 lakh.

R. K Arora, Chairman, Supertech Limited, said, “With progressive law like RERA coming into force and addressing key concerns of both buyers and developers, the real estate market is now beginning to pick up the momentum. The build up in demand is evident in our sales numbers, with Supertech selling 300 residential units in month on month of the current financial year. Thanks to the robust sales, we are on track to achieve our annual sales target of Rs. 3,000 crore rupees in this period.”

“The Company’s decision to increase size of MIG-I and MIG-II category flats under PMAY Scheme from the existing 90 sq. mtrs. to 120 mtrs. and 110 sq. mtrs. to 150 sq. mtrs. respectively as permitted by the Government recently, will enable buyers to acquire bigger flats and avail the subsidy benefit of Rs. 2.50 lacs. This will boost demand and would help the Company achieve the sales target of 3,000 crore rupees”. added Arora.

Supertech recently became 100% RERA compliant with all the new RERA rules and regulations. The company has also delivered more than 30,000 units across 40 million square feet area of residential and commercial spaces. It has presence in Noida, Greater Noida, Gurgaon, Ghaziabad, Meerut, Moradabad, Dehradun, Haridwar, Rudrapur and Bengaluru.

Yash Ved
Yash Ved is a Senior Correspondent at NewsBarons and comes with a decade of experience across leading online and offline publications. A keen observer of the stock index movement, Yash also likes covering Real Estate and the BFSI sector. A financial management and Journalism student, Yash believes learning as a continuous journey and enjoys following the IT and the Pharmaceutical industry and has penned many articles on the subjects.